Magnetar Financial LLC Acquires Shares of 7,660 Hologic, Inc. $HOLX

Key Points

• Magnetar Financial LLC invested approximately $473,000 in Hologic, purchasing 7,660 shares of the medical equipment provider's stock in the first quarter.
• Hologic's stock has received several upgrades, with Royal Bank Of Canada raising its target price from $72.00 to $87.00, reflecting increased analyst optimism.
• The company's latest quarterly earnings beat expectations with an EPS of $1.08, while revenues increased by 1.2% year-over-year to $1.02 billion.

Magnetar Financial LLC purchased a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 7,660 shares of the medical equipment provider's stock, valued at approximately $473,000.

Several other institutional investors have also bought and sold shares of the stock. Beverly Hills Private Wealth LLC boosted its stake in Hologic by 3.6% in the 1st quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider's stock valued at $320,000 after buying an additional 180 shares in the last quarter. Allworth Financial LP raised its position in Hologic by 46.0% in the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after purchasing an additional 216 shares during the last quarter. Baker Avenue Asset Management LP increased its holdings in shares of Hologic by 0.5% in the fourth quarter. Baker Avenue Asset Management LP now owns 42,051 shares of the medical equipment provider's stock valued at $3,031,000 after purchasing an additional 225 shares in the last quarter. Integrated Advisors Network LLC increased its holdings in shares of Hologic by 5.4% in the first quarter. Integrated Advisors Network LLC now owns 5,603 shares of the medical equipment provider's stock valued at $346,000 after purchasing an additional 289 shares in the last quarter. Finally, Townsquare Capital LLC increased its holdings in shares of Hologic by 4.5% in the first quarter. Townsquare Capital LLC now owns 6,763 shares of the medical equipment provider's stock valued at $418,000 after purchasing an additional 293 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Stock Down 0.6%

Shares of NASDAQ HOLX traded down $0.37 during mid-day trading on Wednesday, reaching $66.24. 1,411,645 shares of the company's stock were exchanged, compared to its average volume of 1,620,470. The firm has a market capitalization of $14.73 billion, a price-to-earnings ratio of 27.49, a PEG ratio of 2.44 and a beta of 0.57. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. The business has a fifty day simple moving average of $66.28 and a 200 day simple moving average of $62.57. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.Hologic's quarterly revenue was up 1.2% on a year-over-year basis. During the same period last year, the company earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, equities analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Stephens cut their price target on Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 13th. Mizuho set a $75.00 price target on Hologic in a research note on Thursday, July 31st. Wall Street Zen lowered Hologic from a "buy" rating to a "hold" rating in a research note on Saturday. Citigroup raised Hologic from a "neutral" rating to a "buy" rating and upped their price target for the company from $60.00 to $80.00 in a research note on Wednesday, July 9th. Finally, Royal Bank Of Canada raised Hologic from a "sector perform" rating to an "outperform" rating and upped their price target for the company from $72.00 to $87.00 in a research note on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, Hologic currently has a consensus rating of "Moderate Buy" and an average target price of $78.00.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.